Preprint2025
Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockade
- Published
- 9 October 2025
- Citations
- 0
- Type
- Preprint
- License
- cc0
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Grants 5
- Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy P50CA196510↗
- Targeting tumor innate immune signaling in pancreatic cancer R01CA219697↗
- Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy R01CA244938↗
- Harnessing TNFa Signaling To Improve Therapeutic Response In Pancreatic Cancer R01CA262414↗
- IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA R37CA219697↗